Is fecal calprotectin an accurate marker in the management of Crohn's disease?
Capsule endoscopy
Colonoscopy
Crohn's disease
Fecal calprotectin
Fecal markers
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
30
08
2019
revised:
06
11
2019
accepted:
16
11
2019
pubmed:
4
12
2019
medline:
15
9
2020
entrez:
4
12
2019
Statut:
ppublish
Résumé
Although lacking validated cutoff values, fecal calprotectin (FC), besides C-reactive protein, is considered the standard test for assessing disease activity in Crohn's disease (CD). The aim of the present review is to provide a general overview of the literature addressing the role of FC in the clinical and endoscopic assessment of disease activity in CD, seeking correlations with capsule endoscopy, response to therapy, prediction of relapse, and postoperative recurrence. A systematic search of the literature up to September 2019 was performed using Medline, Embase, and the Cochrane Library. Only papers written in English concerning FC in adult patients affected by CD were included. Pediatric studies, in vitro studies, animal studies, studies on blood/serum samples, and studies analyzing FC in ulcerative colitis or in both CD and ulcerative colitis were excluded. Out of 713 citations, 65 eligible studies were identified. FC showed high accuracy in the assessment of intestinal inflammation and response to therapy, in particular in colonic disease, thus proving a good surrogate marker for these aims. FC is useful in identifying patients at high risk for endoscopic relapse or postoperative recurrence, for optimizing or downstage therapy. Unfortunately, FC performs less well in small bowel CD. FC is an effective fecal marker in the management of CD patients, optimizing the use of endoscopic procedures. Owing to its diagnostic accuracy, FC may represent a cornerstone of the "treat-to-target" management strategy of CD patients.
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-400Informations de copyright
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Basso D, Zambon CF, Plebani M. Inflammatory bowel diseases: from pathogenesis to laboratory testing. Clin Chem Lab Med 2014; 52: 471-481.
Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-513.
Alibrahim B, Aljasser MI, Salh B. Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review. Can J Gastroenterol Hepatol 2015; 29: 157-163.
Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169.
Vázquez-Morón JM, Pallarés-Manrique H, Machancoses FH, Ramos-Lora M, Ruiz-Frutos C. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin. Rev Esp Enferm Dig 2017; 109: 130-136.
Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-46.
Arai T, Takeuchi K, Miyamura M et al. Level of fecal calprotectin correlates with severity of small bowel Crohn's disease, measured by balloon-assisted enteroscopy and computed tomography enterography. Clin Gastroenterol Hepatol 2017; 15: 56-62.
Inokuchi T, Kato J, Hiraoka S et al. Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn's disease. Inflamm Bowel Dis 2016; 22: 1078-1085.
Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13: 1100-1105.
Af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2012; 47: 528-537.
Eder P, Stawczyk-Eder K, Łykowska-Szuber L et al. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease. Pol Arch Med Wewn 2014; 124: 51-57.
Karczewski J, Swora-Cwynar E, Rzymski P, Poniedziałek B, Adamski Z. Selected biologic markers of inflammation and activity of Crohn's disease. Autoimmunity 2015; 48: 318-327.
Gecse KB, Brandse JF, van Wilpe S et al. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 2015; 50: 841-847.
Kawashima K, Ishihara S, Yuki T et al. Fecal calprotectin more accurately predicts endoscopic remission of Crohn's disease than serological biomarkers evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis 2017; 23: 2027-2034.
Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390: 2779-2789.
Sipponen T, Kärkkäinen P, Savilahti E et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-1229.
Iwamoto F, Matsuoka K, Motobayashi M et al. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol 2018; 33: 1984-1989.
Mosli MH, Zou G, Garg SK et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 802-819.
Jones J, Loftus EV Jr, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1218-1224.
Gaya DR, Lyon TDB, Duncan A et al. Faecal calprotectin in the assessment of Crohn's disease activity. Q J Med 2005; 98: 435-441.
Turvill J, Rook L, Rawle M et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterol 2017; 8: 183-188.
Koulaouzidis A, Douglas S, Plevris JN. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index. Dig Dis Sci 2012; 57: 987-993.
Kopylov U, Yung DE, Engel T et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016; 28: 1137-1144.
Hale MF, Drew K, McAlindon ME, Sidhu R. The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn's disease. Eur J Gastroenterol Hepatol 2016; 28: 1145-1150.
Egea-Valenzuela J, Alberca-de-Las-Parras F, Carballo-Álvarez F. Fecal calprotectin as a biomarker of inflammatory lesions of the small bowel seen by videocapsule endoscopy. Rev Esp Enferm Dig 2015; 107: 211-214.
Höög CM, Bark LÅ, Broström O, Sjöqvist U. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease. Scand J Gastroenterol 2014; 49: 1084-1090.
Bar-Gil Shitrit A, Koslowsky B, Livovsky DM et al. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy. Scand J Gastroenterol 2017; 52: 328-333.
Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J. Sipponen T. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol 2011; 9: 124-129.
Sipponen T, Haapamäki J, Savilahti E et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012; 47: 778-784.
Kopylov U, Yablecovitch D, Lahat A et al. Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol 2015; 110: 1316-1323.
Kopylov U, Nemeth A, Koulaouzidis A et al. Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm Bowel Dis 2015; 21: 93-100.
Olsen PA, Fossmark R, Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease-a selection tool for small bowel capsule endoscopy? Scand J Gastroenterol 2015; 50: 272-277.
Aggarwal V, Day AS, Connor S et al. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. Gastrointest Endosc 2017; 86: 1070-1078.
Yousuf H, Aleem U, Egan R, Maheshwari P, Mohamad J, McNamara D. Elevated faecal calprotectin levels are a reliable non-invasive screening tool for small bowel Crohn's disease in patients undergoing capsule endoscopy. Dig Dis 2018; 36: 202-208.
Monteiro S, Barbosa M, Cúrdia Gonçalves T et al. Fecal calprotectin as a selection tool for small bowel capsule endoscopy in suspected Crohn's disease. Inflamm Bowel Dis 2018. https://doi.org/10.1093/ibd/izy098.
Sipponen T, Savilahti E, Kärkkäinen P et al. Fecal calprotectin, lactoferrin and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-1398.
Sipponen T, Bjorkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010; 45: 325-331.
Łykowska-Szuber L, Klimczak K, Eder P et al. Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-α therapy in primary responders with Crohn's disease. Prz Gastroenterol 2016; 11: 232-238.
Nogueira IM, Miszputen SJ, Ambrogini O Jr, Artigiani-Neto R, Carvente CT, Zanon MI. Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin. Arq Gastroenterol 2013; 50: 130-137.
Boschetti G, Garnero P, Moussata D et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease. Inflamm Bowel Dis 2015; 21: 331-336.
Leal RF, Planell N, Kajekar R et al. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy. Gut 2015; 64: 233-242.
Pavlidis P, Gulati S, Dubois P et al. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease. Scand J Gastroenterol 2016; 51: 1447-1452.
Beltrán B, Iborra M, Sáez-González E et al. Fecal calprotectin pretreatment and induction infliximab levels for prediction of primary nonresponse to infliximab therapy in Crohn's disease. Dig Dis 2019; 37: 108-115.
Af Björkesten CG, Jussila A, Kemppainen H et al. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol 2019; 18: 1- 7.
Mao R, Xiao YL, Gao X et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894-1899.
Kallel L, Ayadi I, Matri S et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010; 22: 340-345.
Laharie D, Mesli S, El Hajbi F et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011; 34: 462-469.
Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
Naismith GD, Smith LA, Barry SJ et al. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. J Crohns Colitis 2014; 8: 1022-1029.
Turvill J. Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol 2014; 5: 167-175.
Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Muñoz JE. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab. Scand J Gastroenterol 2016; 51: 442-447.
Delefortrie Q, Schatt P, Grimmelprez A et al. Comparison of the Liaison® calprotectin kit with a well-established point of care test (Quantum Blue-Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up. Clin Biochem 2016; 49: 268-273.
Ye L, Chen BQ, Wang SD, Shi H, Yang Z, Wang FY. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study. Scand J Gastroenterol 2017; 52: 1113-1119.
Roblin X, Duru G, Williet N et al. Development and internal validation of a model using fecal calprotectin in combination with infliximab trough levels to predict clinical relapse in Crohn's disease. Inflamm Bowel Dis 2017; 23: 126-132.
Monteiro S, Dias de Castro F, Leite S, Moreira MJ, Cotter J. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Scand J Gastroenterol 2019; 54: 49-54.
Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 591-599.
Sorrentino D, Terrosu G, Paviotti A et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab-a pilot study. Dig Dis Sci 2012; 57: 1341-1348.
Wright EK, Kamm MA, De Cruz P et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 2015; 148: 938-947.
Garcia-Planella E, Mañosa M, Cabré E et al. Fecal calprotectin levels are closely correlated with the absence of relevant mucosal lesions in postoperative Crohn's disease. Inflamm Bowel Dis 2016; 22: 2879-2885.
Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study. Therap Adv Gastroenterol 2016; 9: 664-670.
Lamb CA, Mohiuddin MK, Gicquel J et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009; 96: 663-674.
Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: a prospective pilot study. United European Gastroenterol J 2013; 1: 368-374.
Boschetti G, Laidet M, Moussata D et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease. Am J Gastroenterol 2015; 110: 865-872.
Orlando A, Modesto I, Castiglione F et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006; 10: 17-22.
Herranz Bachiller MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, Sancho Del Val L, Atienza SR. The utility of faecal calprotectin to predict post-operative recurrence in Crohns disease. Scand J Gastroenterol 2016; 51: 720-726.
Qiu Y, Mao R, Chen BL et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: a meta-analysis of prospective studies. Inflamm Bowel Dis 2015; 21: 315-322.
Lasson A, Strid H, Ohman L et al. Fecal calprotectin one year after ileocaecal resection for Crohn's disease-a comparison with findings at ileocolonoscopy. J Crohns Colitis 2014; 8: 789-795.
Lopes S, Andrade P, Afonso J et al. Correlation between calprotectin and modified Rutgeerts score. Inflamm Bowel Dis 2016; 22: 2173-2181.
Cerrillo E, Moret I, Iborra M et al. A nomogram combining fecal calprotectin levels and plasma cytokine profiles for individual prediction of postoperative Crohn's disease recurrence. Inflamm Bowel Dis 2019; 29: pii: izz053.
Papamichael K, Karatzas P, Mantzaris GJ. Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease. J Crohns Colitis 2013; 7: e700-e701.
Lobatón T, López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013; 7: e641-e651.
Verdejo C, Hervías D, Roncero Ó et al. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease. Eur J Gastroenterol Hepatol 2018; 30: 1521-1527.
Baillet P, Cadiot G, Goutte M et al. Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence. World J Gastroenterol 2018; 24: 641-650.
Lin JF, Chen JM, Zuo JH et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014; 20: 1407-1415.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. National Institute for Health and Care Excellence (NICE). Available on the web site. https://www.nice.org.uk/guidance/dg11
Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol 2015; 29: 369-372.
de Suray N, Salleron J, Vernier-Massouille G, et al. Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A sub-analysis of the STORI study. Poster P274 presented at the 7th Congress of European Crohn's and colitis organisation (ECCO), 2012. Available from URL: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2012/item/p274-close.html
Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013; 50: 53-61.
Labaere D, Smismans A, Van Olmen A et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014; 2: 30-37.
Naismith GD, Smith LA, Barry SJ et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013; 37: 613-621.
Du L, Foshaug R, Huang VW et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol 2018; 52: 235-240.
Di Ruscio M, Vernia F, Ciccone A, Frieri G, Latella G. Surrogate fecal biomarkers in inflammatory bowel disease: rivals or complementary tools of fecal calprotectin? Inflamm Bowel Dis 2017; 24: 78-92.
Ahmed I, Greenwood R, Costello B, Ratcliffe N, Probert CS. Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Aliment Pharmacol Ther 2016; 43: 596-611.